Safety of investigative bronchoscopy in the Severe Asthma Research Program Wendy C. Moore, MD, Michael D. Evans, MS, Eugene R. Bleecker, MD, William W. Busse, MD, William J. Calhoun, MD, Mario Castro, MD, Kian Fan Chung, MD, Serpil C. Erzurum, MD, Douglas Curran-Everett, PhD, Raed A. Dweik, MD, Benjamin Gaston, MD, Mark Hew, MD, Elliot Israel, MD, Martin L. Mayse, MD, Rodolfo M. Pascual, MD, Stephen P. Peters, MD, PhD, Lori Silveira, MS, Sally E. Wenzel, MD, Nizar N. Jarjour, MD Journal of Allergy and Clinical Immunology Volume 128, Issue 2, Pages 328-336.e3 (August 2011) DOI: 10.1016/j.jaci.2011.02.042 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Change in FEV1 after bronchoscopy in the 4 groups of subjects. Shown is the percent change in percent predicted FEV1 from the first FEV1 before albuterol administration to the lowest FEV1 after bronchoscopy. There was no statistically significant difference in the distribution of percent change in percent predicted FEV1 among the groups (P = .30). Journal of Allergy and Clinical Immunology 2011 128, 328-336.e3DOI: (10.1016/j.jaci.2011.02.042) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 2 Change in FEV1 after bronchoscopy for individual subjects. There is a mild relationship (r = –0.21; P < .0001) between better baseline lung function and greater percent decrease in FEV1. The closed circles represent the subjects who had asthma exacerbations. The closed triangles are subjects who went to the ED with other complaints. Journal of Allergy and Clinical Immunology 2011 128, 328-336.e3DOI: (10.1016/j.jaci.2011.02.042) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions